ATE415415T1 - Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist - Google Patents

Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist

Info

Publication number
ATE415415T1
ATE415415T1 AT03763864T AT03763864T ATE415415T1 AT E415415 T1 ATE415415 T1 AT E415415T1 AT 03763864 T AT03763864 T AT 03763864T AT 03763864 T AT03763864 T AT 03763864T AT E415415 T1 ATE415415 T1 AT E415415T1
Authority
AT
Austria
Prior art keywords
group
amino acid
glucagon receptor
bicyclic
receptor antagonists
Prior art date
Application number
AT03763864T
Other languages
German (de)
English (en)
Inventor
Olivier Potterat
Ruediger Streicher
Klaus Wagner
Till Maurer
Juergen Mack
Stefan Peters
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE415415T1 publication Critical patent/ATE415415T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT03763864T 2002-07-17 2003-07-15 Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist ATE415415T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02015907 2002-07-17

Publications (1)

Publication Number Publication Date
ATE415415T1 true ATE415415T1 (de) 2008-12-15

Family

ID=30011078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03763864T ATE415415T1 (de) 2002-07-17 2003-07-15 Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist

Country Status (8)

Country Link
EP (1) EP1525218B1 (cg-RX-API-DMAC10.html)
JP (1) JP4616000B2 (cg-RX-API-DMAC10.html)
AT (1) ATE415415T1 (cg-RX-API-DMAC10.html)
AU (2) AU2003260306A1 (cg-RX-API-DMAC10.html)
CA (1) CA2489189A1 (cg-RX-API-DMAC10.html)
DE (1) DE60324936D1 (cg-RX-API-DMAC10.html)
ES (1) ES2316820T3 (cg-RX-API-DMAC10.html)
WO (2) WO2004007524A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
SG11201407316QA (en) * 2012-05-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of hyperglycemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139526A (en) * 1977-12-01 1979-02-13 Merck & Co., Inc. Somatostatin analogs

Also Published As

Publication number Publication date
JP2006505507A (ja) 2006-02-16
DE60324936D1 (de) 2009-01-08
CA2489189A1 (en) 2004-01-22
ES2316820T3 (es) 2009-04-16
AU2003260306A1 (en) 2004-02-02
JP4616000B2 (ja) 2011-01-19
WO2004007524A2 (en) 2004-01-22
EP1525218A1 (en) 2005-04-27
WO2004007535A1 (en) 2004-01-22
EP1525218B1 (en) 2008-11-26
AU2003246702A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
AU2010310665B2 (en) Peptidic GLP-2 agonists
ATE517119T1 (de) Einzelketteninsulin
NO20011386D0 (no) Nye metoder for fremvisning av (poly)peptider/proteiner pÕ bakteriofage partikler via disulfidbindinger
ATE547430T1 (de) Multimere des cytokinrezeptors zcytor17
CO6241137A2 (es) Antagonistas ciclicos de peptido cxcr4
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
ATE549028T1 (de) Stabile analoga von glp-1
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
ATE417595T1 (de) Keratin-bindende polypeptide
PE20091067A1 (es) Variantes de peptidos natriureticos de tipo c
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
JP6811190B2 (ja) プロテアーゼ耐性脂質付加ｇｌｐ−１類似体
JP2017502003A (ja) プロテアーゼ耐性ペプチド
ATE474850T1 (de) Analoga von peptiden der relaxin-superfamilie
Karhu et al. Isolation of new ligands for orphan receptor MRGPRX1—hemorphins LVV-H7 and VV-H7
DE60324936D1 (de) Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist
Jinsmaa et al. Designing of an orally active complement C3a agonist peptide with anti-analgesic and anti-amnesic activity
EP2120985B1 (en) FN-38 peptides for use in the treatment of psychotic and anxiety disorders
NO20082127L (no) Antagonister mot interaksjon av PF4 og Rantes
KR940007059A (ko) 변형된 혈소판 인자-4
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
ATE500324T1 (de) Inhibitoren der enzymaktivität der endooligopeptidase a (eopa) und ihre verwendungen
ATE417061T1 (de) Scorpionpeptid als blutdrucksenkendes mittel
DE50310131D1 (de) Peptide mit hohem cysteingehalt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1525218

Country of ref document: EP